pSivida has signed a funded technology evaluation agreement with a biopharmaceutical company to evaluate pSivida's Tethadur protein/antibody delivery technology in the field of ophthalmology.
Tethadur, which uses an injectable, bioerodible, nanostructured, porous BioSilicon material for drug delivery, is designed to provide sustained delivery of large biologic molecules, including proteins, antibodies and peptides.
Nanotechnology was used to manufacture the sizes of the pores in the BioSilicon material to accommodate specific protein, peptide or antibody molecules that are then released on a sustained basis over time as the material bioerodes.
pSivida president and CEO Paul Ashton said the commercial agreement for Tethadur, based on BioSilicon, the second key technology platform, following the company's three approved products utilizing our Durasert technology platform.
"A sustained delivery system for these types of molecules would offer a significant clinical advance in the ophthalmic area where injections of protein based drugs into the eye every one or two months are sometimes required," Ashton added.